磁共振成像引导单次分割肺部立体定向消融放疗后的局部控制与毒性
研究报道2018至2022年50例连续患者接受0.35 T直线加速器磁共振成像引导单次分割肺部立体定向消融放疗的长期结局。中位随访18.1个月时2年生存率82%,中位随访16.1个月时局部复发2例(4%),3年局部控制率97%,仅1例发生≥3级毒性(胸壁疼痛)。
要点
- 0.35 T直线加速器磁共振成像引导单次分割肺部立体定向消融放疗采用重复屏气与自动束流门控。
- 69%患者为原发性非小细胞肺癌,中位计划靶体积11.2 cc,80%大体肿瘤体积距胸壁≤2.5 cm。
- 2年生存率82%(原发性非小细胞肺癌89%,转移瘤62%),3年局部控制率97%,≥3级毒性1例。
核心结论
- 在0.35 T直线加速器上采用重复屏气与自动束流门控实施磁共振成像引导单次分割肺部立体定向消融放疗,可获得良好的肿瘤控制和低毒性。
研究设计与样本
- 经伦理批准的机构数据库纳入2018至2022年接受单次分割立体定向消融放疗的肺部肿瘤连续患者50例,69%为原发性非小细胞肺癌。
- 放疗前行屏气3D磁共振模拟扫描(true FISP序列)和屏气3D CT扫描,大体肿瘤体积先在屏气CT上勾画并与3D磁共振扫描勾画比较后最终确定。
- 立体定向消融放疗计划采用step-and-shoot调强放疗束,计划靶体积为大体积肿瘤体积加5 mm外扩,门控窗为3 mm。
- 放疗在重复屏气中实施,采用自动束流门控并在矢状面磁共振平面上连续可视化大体肿瘤体积。
主要发现
- 中位计划靶体积为11.2 cc(范围3.9-53.5),80%的大体肿瘤体积位于距胸壁≤2.5 cm处。
- 处方剂量为34 Gy(58%)、30 Gy(32%)或20-28 Gy之间(10%)。
- 中位随访18.1个月(95%CI 12.8-23.5)时,2年生存率为82%(原发性非小细胞肺癌89%,转移瘤62%)。
- 中位随访16.1个月(95%CI 11.2-21.1)时,2例患者(4%)出现局部复发,3年局部控制率为97%。
- 仅1例患者发生≥3级毒性(胸壁疼痛)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Magnetic resonance imaging (MR)-guided radiotherapy permits continuous intrafraction visualization and use of automatic triggered beam delivery, with use of smaller planning target volumes (PTV). We report on long-term clinical outcomes following MR-guided single fraction (SF) lung SABR on a 0.35 T linac. MATERIALS AND METHODS: Details of patients treated with SF-SABR for lung tumors were accessed from an ethics approved institutional database. A breath-hold 3D MR simulation scan was performed using a true FISP sequence, followed by a breath-hold 3D CT scan. The gross tumor volume (GTV) was first contoured on the breath-hold CT scan, which was then compared with contours on the 3D MR scan, before the GTV was finalized. SABR plans used step-and-shoot IMRT beams to a PTV derived by adding a 5 mm margin to the breath-hold GTV, and a 3 mm gating window was used. SABR was delivered during repeated breath-holds, using automatic beam gating with continuous visualization of the GTV in a sagittal MR plane. RESULTS: Between 2018-2022, 50 consecutive patients were treated, and 69% had a primary non-small cell lung cancer. Median PTV was 11.2 cc (range 3.9-53.5); 80% of GTV's were located ≤2.5 cm from the chest wall. Prescribed doses were 34 Gy (in 58%), 30 Gy (32%), or between 20-28 Gy (10%). After a median follow-up of 18.1 months (95% CI 12.8-23.5), the 2-year survival was 82% (89% for primary NSCLC and 62% for metastases). After a median follow-up of 16.1 months (95% CI 11.2-21.1), local recurrences developed in 2 patients (4%). The 3-year local control rate was 97%, and just 1 patient developed grade ≥3 toxicity (chest wall pain). CONCLUSION: MR-guided SF-SABR delivery to lung tumors on a 0.35 T linac, using repeated breath-holds with automatic beam gating, achieves good tumor control and low toxicity.
引用
- Tekatli H, Palacios MA, Schneiders FL, et al. Local control and toxicity after magnetic resonance imaging (MR)-guided single fraction lung stereotactic ablative radiotherapy. Radiother Oncol. 2023. PMID: 37516364. doi:10.1016/j.radonc.2023.109823
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。